|
|
|
| 
|
|
|
My Recent Searches
|
|
|
|
|
|
|
|
|
Pyxis Oncology, Inc. (PYXS) |
|
|
$0.00 0.00 (0.00%) as of 4:30 Tue 11/30
|
|
Download |
|
|
| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
32,761,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$ - $ |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Pyxis Oncology is engaged in the development of therapeutics to treat cancers. Co. develops its product candidates to kill tumor cells and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion. Co. has developed a portfolio of antibody drug conjugate product candidates and monoclonal antibody (mAb) preclinical discovery programs that it is developing as monotherapies and in combination with other therapies. Co.'s product candidates, PYX-201 and PYX-202 are in IND-enabling studies. In addition, PYX-203 is in preclinical development and it has additional preclinical mAb discovery programs.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
41,426 |
1,853,020 |
| Total Buy Value |
$0 |
$0 |
$73,441 |
$5,073,440 |
| Total People Bought |
0 |
0 |
2 |
3 |
| Total Buy Transactions |
0 |
0 |
7 |
8 |
| Total Shares Sold |
0 |
0 |
36,558 |
1,782,319 |
| Total Sell Value |
$0 |
$0 |
$81,462 |
$5,406,033 |
| Total People Sold |
0 |
0 |
1 |
2 |
| Total Sell Transactions |
0 |
0 |
5 |
6 |
| End Date |
2024-01-21 |
2023-10-20 |
2023-04-21 |
2022-04-21 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Wadhane Jitendra |
SVP, Chief Accounting OfficerO |
• – – |
2022-08-03 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
43,648 |
|
- |
|
| Barclays Plc |
10% Owner |
– – • |
2022-04-25 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
3,477,975 |
|
- |
|
| Chin Mark |
Former Director |
– – – |
2022-04-21 |
4 |
S |
$3.05 |
$5,324,571 |
I/I |
(1,745,761) |
0 |
|
- |
|
| Lewis-Hall Freda C |
|
• • – |
2022-03-31 |
4 |
A |
$0.00 |
$0 |
D/D |
66,831 |
66,831 |
|
- |
|
| Civik Thomas |
|
• • – |
2022-03-31 |
4 |
A |
$0.00 |
$0 |
D/D |
66,831 |
66,831 |
|
- |
|
| Yanchik Connealy Pamela |
Chief Financial Officer |
• • – |
2022-03-31 |
4 |
A |
$0.00 |
$0 |
D/D |
247,524 |
247,524 |
|
- |
|
| Flavin John L |
|
• • – |
2022-03-31 |
4 |
A |
$0.00 |
$0 |
D/D |
66,831 |
238,441 |
|
- |
|
| Sullivan Lara |
Chief Executive Officer |
• • – |
2022-03-31 |
4 |
A |
$0.00 |
$0 |
D/D |
742,574 |
1,041,363 |
|
- |
|
| Feingold Jay |
Chief Medical Officer |
• • – |
2022-03-31 |
4 |
A |
$0.00 |
$0 |
D/D |
306,930 |
350,680 |
|
- |
|
| Chin Mark |
|
• • – |
2022-03-31 |
4 |
A |
$0.00 |
$0 |
D/D |
66,831 |
66,831 |
|
- |
|
| Cline Darren S |
|
• • – |
2022-03-31 |
4 |
A |
$0.00 |
$0 |
D/D |
66,831 |
76,831 |
|
- |
|
| Cline Darren S |
Director |
– • – |
2021-12-08 |
4 |
B |
$9.39 |
$93,885 |
D/D |
10,000 |
10,000 |
2.39 |
- |
|
| Civik Thomas |
Director |
– • – |
2021-11-18 |
4 |
B |
$12.74 |
$200,018 |
I/I |
15,700 |
15,700 |
2.1 |
- |
|
| Flavin John L |
|
• • – |
2021-10-13 |
4 |
A |
$0.00 |
$0 |
D/D |
2,388 |
171,610 |
|
- |
|
| Cormorant Private Healthcare Fund Iii Lp |
Former 10% Owner |
– – – |
2021-10-13 |
4 |
B |
$16.00 |
$7,200,000 |
I/I |
450,000 |
1,118,854 |
0.01 |
- |
|
| Cormorant Private Healthcare Fund Iii Lp |
Former 10% Owner |
– – – |
2021-10-13 |
4 |
A |
$0.00 |
$0 |
I/I |
668,854 |
668,854 |
|
- |
|
| Chin Mark |
|
• • – |
2021-10-13 |
4 |
B |
$16.00 |
$5,000,000 |
I/I |
312,500 |
1,745,761 |
0.01 |
- |
|
| Chin Mark |
|
• • – |
2021-10-13 |
4 |
A |
$0.00 |
$0 |
I/I |
1,433,261 |
1,433,261 |
|
- |
|
| Bayer Aktiengesellschaft |
Former 10% Owner |
– – – |
2021-10-13 |
4 |
A |
$0.00 |
$0 |
D/D |
2,742,338 |
2,742,338 |
|
- |
|
| Feingold Jay |
Chief Medical Officer |
• • – |
2021-10-07 |
4 |
A |
$0.00 |
$0 |
D/D |
43,750 |
43,750 |
|
- |
|
| Sullivan Lara |
Chief Executive Officer |
• • – |
2021-10-07 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
298,789 |
|
- |
|
| Flavin John L |
|
– • – |
2021-10-07 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
169,222 |
|
- |
|
| Herbst Ronald |
Chief Scientific Officer |
• – – |
2021-10-07 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
90,422 |
|
- |
|
23 Records found
|
1
|
Page 1 of 1 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
